Shattuck Labs, Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
Shattuck Labs, Inc. (STTK) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of -$220.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2022-11-09
- Shattuck Labs, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2022-09-30 was -$79.00K.
- Shattuck Labs, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2022-06-30 was -$174.00K, a 129.15% decline year-over-year.
- Shattuck Labs, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2022-03-31 was $33.00K.
- Shattuck Labs, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2021-09-30 was $0.00.
- Shattuck Labs, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2020 was -$1.00K, a 100.60% decline from fiscal 2019.
- Shattuck Labs, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2019 was $166.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month as first filed | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month as first filed | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month as first filed | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|---|---|---|
| 2022-09-30 | -$79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$253.00K derived: sum of 2 quarters · filed 2022-11-09 | -$220.00K 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | -$174.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$141.00K 10-Q · filed 2022-08-11 | |||||
| 2022-03-31 | $33.00K 10-Q · filed 2022-05-12 | ||||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $597.00K derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | -$774.00K 10-Q · filed 2021-11-09 | -$23.00K derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $597.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | -$2.00K 10-Q · filed 2021-08-12 | -$23.00K derived: sum of 3 quarters · filed 2022-08-11 | -$59.00K derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | -$597.00K 10-Q · filed 2022-05-12 | $0.00 10-Q · filed 2021-05-10 | -$620.00K derived: sum of 2 quarters · filed 2022-05-12 | -$656.00K derived: sum of 3 quarters · filed 2022-05-12 | -$636.00K derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$59.00K derived: sum of 2 quarters · filed 2021-11-09 | -$39.00K derived: sum of 3 quarters · filed 2021-11-09 | -$1.00K 10-K · filed 2021-03-16 | |||
| 2020-09-30 | -$36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$16.00K derived: sum of 2 quarters · filed 2021-11-09 | $22.00K 10-Q · filed 2021-11-09 | $106.00K derived: sum of 4 quarters · filed 2021-11-09 | |||
| 2020-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $58.00K 10-Q · filed 2021-08-12 | $142.00K derived: sum of 3 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $38.00K 10-Q · filed 2021-05-10 | $122.00K derived: sum of 2 quarters · filed 2021-05-10 | |||||
| 2019-12-31 | $84.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $166.00K 10-K · filed 2021-03-16 | |||||
| 2019-09-30 | $82.00K 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |